The Medical Advisor

Researchers delving into the timing of subsequent colonoscopies found that for some people, the risks are no different if they wait 15 years instead of 10. The invasive and expensive nature of colonoscopies makes determining how to maximize their usefulness—particularly when it comes to follow-up screenings—a prominent topic of research. It’s undisputed that the surgical-based test can save lives, but the timing remains a moving target. Three years ago, the U.S. Preventive Services Task Force lowered the recommended age for the first colorectal cancer screening by five years—from 50 years of age to 45. Now, the gap between the first and second tests is being scrutinized. Long-term data used in a JAMA Oncology study published May 2 suggests it may be time to move the follow-up screening back five years in certain circumstances. Specifically, the study indicates that anyone who doesn’t have a family history of colorectal cancer and whose first colonoscopy was free of polyps—abnormal...

Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press release that added over $5 billion to its market capitalization — with one major caveat. Summit Therapeutics said its experimental cancer drug beat Merck’s flagship immunotherapy Keytruda in a head-to-head Phase 3 study of non-small cell lung cancer patients in China. The Miami-based biotech said it was the first time a cancer drug has pulled off the feat of toppling Keytruda in this type of cancer. The readout triggered a multibillion-dollar stock swing, with Summit $SMMT closing up 272% on Thursday and commanding a $7.7 billion market capitalization. Merck saw its shares $MRK fall just over 1%. For all the market excitement, the results come from an interim analysis described in a press release without disclosing specific clinical results. Summit said the full dataset will be presented later this year at a medical confe...

Joe Tipp’s Protocol (the original version) – complementary cancer treatment Fenbendazole 222 mg. Take 1 capsule three days a week, once a day after a fatty meal.* Then take no fenbendazole for four days. Repeat this cycle every week. Bio-Available Curcumin 600 mg. Take 1 capsule two times a day after breakfast and lunch with no pauses. CBD oil 25 mg. Take 1-2 drops (total ~25 mg) under the tongue every day before sleep. *- fenbendazole is really hydrophobic and is poorly absorbed from the intestinal tract. Taking it with or after a meal improves absorption. Joe Tipp’s Protocol (the modified, stronger version) – complementary cancer treatment Fenbendazole 222 mg. Take 1 capsule every day once after a fatty meal with no pauses.** Bio-Available Curcumin 600 mg. Take 1 capsule two times a day after breakfast and lunch with no pauses. CBD oil 25 mg. Take 1-2 drops (total ~25 mg) under the tongue...

Rick Alderson was a retired sawmill worker who was diagnosed with terminal colon cancer in November 2020. He experienced excruciating pain in his bowels for months; then, a gastroenterologist found a large tumor in his rectum and told him and his wife he only had six months to live. To the oncologist, Mr. Alderson “was a dead man walking,” Mr. Alderson’s wife, Eve Alderson, told The Epoch Times. Doctors were against starting him on treatment due to Mr. Alderson’s age and the severity of his cancer, but Mr. and Mrs. Alderson determined that their fate was in God’s hands and decided to do whatever they could. Mr. Alderson got started with 10 rounds of radiation therapy. Initially, his carcinoembryonic antigen (CEA), a marker for tumor activity, was significantly elevated at 480 nanograms per milliliter (ng/mL). A month later, he started chemotherapy. By then, his CEA levels had risen to 1,498 ng/mL. By the time Mr. Alderson started treatment, his colon cancer had metastasized and spread ...